Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.

Frontiers in oncology·2026
Same author

Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma.

Clinical lung cancer·2026
Same author

Treatment and Outcomes for Acute Ischemic Stroke in Cardiomyopathy Patients With Heart Failure: A Retrospective Cross-Sectional Study.

Cardiology in review·2026
Same author

Bidirectional coupling among EMT, AXL-RB1 signaling and lineage switch drives resistance to osimertinib and worse clinical outcomes in NSCLC.

bioRxiv : the preprint server for biology·2026
Same author

HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer.

Molecular cancer therapeutics·2026
Same author

BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCER.

Cancer discovery·2026

Related Experiment Video

Updated: May 14, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Farletuzumab in lung cancer.

Anish Thomas1, Julia Maltzman, Raffit Hassan

  • 1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.

Lung Cancer (Amsterdam, Netherlands)
|January 30, 2013
PubMed
Summary

Folate receptor α (FOLR1) is a promising target for lung cancer therapy. Farletuzumab, an antibody targeting FOLR1, shows potential in treating metastatic lung adenocarcinoma with high FOLR1 expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Folate is crucial for cell proliferation, making folate pathways potential targets for anti-cancer drugs.
  • Folate receptor alpha (FOLR1) is overexpressed in many cancers, including non-small cell lung cancer (NSCLC), particularly adenocarcinoma.
  • FOLR1's specific expression in tumors and high affinity for folate make it an attractive therapeutic target.

Purpose of the Study:

  • To evaluate the efficacy and safety of farletuzumab, a FOLR1-targeting monoclonal antibody, in patients with metastatic lung adenocarcinoma.
  • To investigate farletuzumab's potential as a targeted therapy for FOLR1-expressing lung cancers.

Main Methods:

  • Pre-clinical studies demonstrated farletuzumab's ability to induce cytotoxicity in FOLR1-expressing cells and inhibit tumor growth in animal models.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Experiment Videos

Last Updated: May 14, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

  • Phase I/II clinical trials assessed farletuzumab's tolerability as a single agent and in combination with chemotherapy.
  • An ongoing Phase II, double-blind, placebo-controlled study is evaluating farletuzumab in patients with FOLR1-expressing metastatic lung adenocarcinoma.

    • Main Results:

    • Pre-clinical data showed targeted cytotoxicity and tumor growth inhibition.
    • Phase I/II trials indicated farletuzumab was well-tolerated, with no additive toxicity when combined with chemotherapy.
    • The ongoing Phase II study aims to confirm efficacy in a larger patient cohort.

    Conclusions:

    • Farletuzumab is a well-tolerated agent with pre-clinical evidence of anti-tumor activity.
    • Targeting FOLR1 represents a viable strategy for treating metastatic lung adenocarcinoma.
    • Further evaluation in the ongoing Phase II trial is critical to establish farletuzumab's clinical benefit.